• Toremifene: Identity and Evidence Scope

  2026-10-20

  A source-limited overview of Toremifene’s documented identity, estrogen-receptor mechanism, and reported cancer-model findings.

• Cariprazine (RGH-188): Receptor Pharmacology

  2026-10-19

  Cariprazine, also identified as RGH-188, is described by the supplier as a dopamine D3/D2-focused antipsychotic candidate with potential relevance to schizophrenia research, bipolar disorder research, and addiction-related neuroscience. The available evidence here is limited to product information rather than a matched research paper.

• (R)-MG132: Identity, Mechanism and Evidence Scope

  2026-10-19

  APExBIO describes (R)-MG132 as a stereoisomeric MG-132 variant with markedly reduced inhibition of the 20S proteasome chymotrypsin-like activity and weaker cellular cytotoxicity. Its documented role is a negative control in ubiquitin-proteasome system research, but the available product information does not provide quantitative assay data, independent replication, or model-specific evidence.

• Anti-AMPK Alpha Antibody: Evidence and Scope

  2026-10-18

  The APExBIO listing identifies MA1202 as a rabbit monoclonal antibody named for AMPK alpha, but provides no product description or identity-matched research evidence in the available material. Its name supports only a cautious interpretation of intended molecular recognition; it does not establish epitope, isoform specificity, application performance, binding selectivity, or a validated mechanism of signal generation.

• 2X HyperFusion: Evidence and Scope

  2026-10-17

  APExBIO describes K1039 as a premixed high-fidelity PCR reagent built around a fusion polymerase with 5′→3′ synthesis and 3′→5′ proofreading. Its fidelity, fragment-size, processivity, and blunt-end claims are supplier-reported properties; without identity-matched research evidence, they are not independently validated across templates or applications.

• CGK733: Identity, Mechanism, and Evidence Boundaries

  2026-10-16

  The available APExBIO product listing identifies CGK733 as catalog item A8624 but provides no description, target, chemical structure, assay data, or identity-matched research paper. Accordingly, a defensible overview can define the product’s catalog provenance and clarify what remains unknown, but it cannot establish a mechanism, biological activity, measurement principle, or research outcome.

• EZ Cap™ CBEmax mRNA (m1Ψ): Evidence and Scope

  2026-10-16

  APExBIO documents R1044 as EZ Cap™ CBEmax mRNA (m1Ψ), a cytosine base-editor mRNA intended for genome-editing research. The available material supports catalog identity and a broad interpretation of sequence-based base-editing measurements, but provides no identity-matched study establishing editing activity, fidelity, kinetics, or applicability in a particular biological model.

• DMOG in a Multimaterial Bone Regeneration Scaffold

  2026-10-15

  A literature-focused analysis of a 2026 study combining DMOG, BMP-4, MgO, mesoporous silica nanoparticles, and dual-material bioprinting for vascularized cranial bone repair. The findings support an association between the integrated scaffold design, HIF-1α-related signaling, angiogenic readouts, and new bone formation, but they do not isolate DMOG’s contribution or establish clinical applicability.

• DMOG and the Evidence for Vascularized Bone Repair

  2026-10-15

  A mechanistic editorial on how Dimethyloxalylglycine was used as part of a BMP-4/DMOG scaffold strategy, what the reported HIF-1α, angiogenic, osteogenic, micro-CT, and histological findings establish, and why the study cannot isolate DMOG-specific causality or establish clinical efficacy.

• DiscoveryProbe Library: Evidence and Scope

  2026-10-14

  The DiscoveryProbe™ Metabolism-related Compound Library (SKU L1032) is described by APExBIO as a 493-compound collection spanning metabolic enzymes and lipid-regulatory pathways. Its documented value is as a broad chemical resource for hypothesis generation and assay-based interrogation, not as independently demonstrated evidence of target engagement, pathway causality, or therapeutic activity.

• NU7441 and the Limits of HIV Reservoir Evidence

  2026-10-14

  The cited Cell Cycle study supports a research hypothesis linking HIV latency with altered telomere biology and DNA-damage vulnerability, but it does not establish NU7441 as a validated HIV-reservoir intervention or demonstrate reservoir reduction in vivo.

• IGF2BP2, Glycolysis, and Ovarian Cancer

  2026-10-13

  Liang and colleagues combine single-cell and bulk transcriptomics with genetic, metabolic, RNA-binding, and pharmacological evidence to examine IGF2BP2 in ovarian cancer. The findings support a context-specific role for IGF2BP2 in malignant-cell proliferation, survival, and glycolysis, but remain preclinical and do not establish clinical efficacy or show that 2-NBDG was used in the study.

• Multiplexed CRISPR: Promise and Limits

  2026-10-13

  A 2025 review examines how multiplexed CRISPR–Cas systems can perturb several genomic targets at once, generate structural variation, regulate gene expression, and selectively stress cells. Its conclusions are a literature synthesis rather than new experimental evidence, and they do not establish the safety, efficacy, or clinical applicability of any particular guide-RNA product.

• Dimethyloxalylglycine (DMOG): Evidence Scope

  2026-10-12

  APExBIO lists Dimethyloxalylglycine (DMOG; SKU A4506) as a research-use compound described as a cell-permeable competitive inhibitor of PHD enzymes. Its documented conceptual scope includes hypoxia-inducible factor stabilization, oxygen sensing, hypoxia signaling, and selected inflammation research. Because no specific reference paper was available, the product listing’s mechanistic and model-related claims should be treated as provisional rather than independently established evidence.

• SIX1 and Lipid Synthesis in Liver Cancer

  2026-10-12

  A 2024 Advanced Science study proposes that SIX1 connects oncogenic transcriptional regulation with de novo lipogenesis in liver cancer through AIB1 and HBO1/KAT7, while an insulin–DGUOK-AS1–miR-145-5p axis regulates SIX1 expression. The findings support a mechanistic model linking lipid production with cancer-cell growth, invasion, and metastasis, but the evidence remains bounded by the study’s experimental systems, association-based patient analyses, and the absence of clinical validation.

8538 records 1/570 page Next 12345 下5页 Last page